Intravitreal topotecan
Phase 2Small molecule
Intravitreal topotecan is one of 12 small molecule programs targeting Proliferative Vitreoretinopathy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Proliferative Vitreoretinopathy
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Adrucil
EElorac, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Trexall
Jazz PharmaceuticalsPhase 2
Hycamtin
MMeitheal
Phase 1
Rhopressa
FFalcon
Phase 2
Intravitreal topotecan
UUnity Health Toronto
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intravitreal topotecan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUnity Health Toronto